Taysha Gene Therapies TSHA Cash Flow Statement (2020-2026)

NASDAQ TSHA
$4.92 -0.07 (-1.40%)
As of: Sep 30, 2026 · 12:27 PM EDT
Reported Financials

Taysha Gene Therapies Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Taysha Gene Therapies reported cash from operations of -$40.42M and free cash flow of -$40.42M for the quarter ended Jun 2026, down 100.3% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-51.22M-50.41M-50.32M-34.12M-26.54M-55.27M-17.93M-24.82M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M-25.44M-40.91M-45.03M
Depreciation and Depletion
0.20M0.20M0.30M0.30M0.30M0.39M0.33M0.40M0.30M0.40M0.33M0.30M0.30M0.30M0.30M0.30M0.20M0.30M0.30M0.40M
Share-based Compensation
5.09M4.96M5.33M4.14M4.47M4.10M1.68M2.22M2.04M1.97M3.20M3.33M3.36M3.22M3.29M3.19M3.29M3.53M5.55M5.81M
Asset Writedowns and Impairment
0.62M0.45M4.84M
Cash from Operations
-31.93M-40.26M-40.94M-33.35M-28.81M14.71M-20.18M-18.77M-17.95M-16.12M-19.80M-21.50M-21.61M-18.31M-22.02M-20.18M-24.17M-26.72M-40.88M-40.42M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
0.20M0.20M0.30M0.30M0.30M0.39M0.33M0.40M0.30M0.40M0.33M0.30M0.30M0.30M0.30M0.30M0.20M0.30M0.30M0.40M
Change in Working Capital
Change in Account Payables
13.62M-1.51M2.54M3.67M-9.43M-4.59M0.36M1.76M-3.19M-1.23M3.98M-1.61M-3.78M-1.50M0.92M3.00M-1.95M-2.13M1.29M4.56M
Change in Accured Expenses
-2.87M5.36M-0.78M-7.68M-0.12M-0.75M-0.25M-1.07M-2.94M-2.02M0.42M-2.38M0.43M0.11M-2.12M0.73M5.01M2.67M-5.15M0.86M
Other Working Capital Changes
-1.75M1.83M-0.27M0.19M-1.90M35.54M-4.71M-2.40M-4.75M-3.60M-3.41M-1.11M-1.79M-2.02M-2.30M-1.99M-5.49M0.79M0.65M
Investing Activities
Capital Expenditures
3.50M8.27M8.43M7.86M2.02M2.31M3.90M-0.05M0.02M0.14M0.20M0.04M-0.00M0.38M0.00M0.11M0.25M0.02M-0.00M
Change in Intangibles
0.50M0.25M3.00M0.25M1.00M0.14M0.38M3.00M
Cash from Investing Activities
-4.00M-8.52M-11.43M-8.11M-3.02M-2.37M-3.90M0.05M-3.49M-0.01M-0.14M-0.20M-0.04M0.01M-0.37M0.06M-0.05M-0.25M-3.02M0.00M
Financing Activities
Other financing activities
-0.23M-0.53M0.06M-0.33M-0.03M-0.12M-0.10M0.65M-0.03M-0.01M-0.17M0.04M-0.08M0.12M-0.28M-0.09M0.02M0.07M
Debt Issuance and Repayment
Long-Term Debt Issuances
Long-Term Debt Repayments
Change in Capital Stock
Net Equity Issued and Repurchased
0.28M11.36M-11.39M0.05M0.45M0.03M0.06M0.07M0.12M1.02M0.52M0.44M
Misc.
Cash from Financing Activities
9.11M-0.11M11.07M-0.10M41.23M-0.37M0.38M140.63M-4.25M-0.02M70.47M6.59M-0.36M-0.05M216.29M8.80M49.56M0.71M216.66M
Change in Cash
-5.96M-39.67M-52.47M-30.39M-31.93M53.57M-24.45M-18.34M119.19M-20.38M-19.96M48.76M-15.05M-18.65M-22.44M196.17M-15.42M22.59M-43.19M176.23M
Free Cash Flow
-35.44M-48.53M-49.37M-41.22M-30.83M12.40M-24.09M-18.72M-17.95M-16.13M-19.94M-21.70M-21.65M-18.31M-22.40M-20.18M-24.27M-26.97M-40.90M-40.42M
Net Cash Flow
-35.94M-39.67M-52.47M-30.39M-31.93M53.57M-24.45M-18.34M119.19M-20.38M-19.96M48.76M-15.05M-18.65M-22.44M196.17M-15.42M22.59M-43.19M176.23M

Taysha Gene Therapies Cash Flow Statement API

Pull Taysha Gene Therapies's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TSHA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY